Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026
Rhea-AI Summary
Liquidia (Nasdaq: LQDA) will report full year 2025 financial results on March 5, 2026. A live webcast is scheduled for 8:30 a.m. Eastern Time to discuss results and provide a corporate update. A rebroadcast will be archived on the company website for one year.
Positive
- None.
Negative
- None.
News Market Reaction – LQDA
In the Feb 26 session, LQDA gained 2.63%, reflecting a moderate positive market reaction. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Clinical data update | Positive | +0.6% | Announcement of multiple clinical posters on treprostinil programs at PVRI 2026. |
| Jan 09 | Prelim sales update | Positive | +12.9% | Preliminary 2025 YUTREPIA net sales and cash flow metrics highlighted commercial traction. |
| Jan 07 | Conference presentation | Positive | +0.9% | CEO presentation scheduled at the J.P. Morgan Healthcare Conference with webcast access. |
| Nov 03 | Investor conferences | Positive | +3.5% | Planned business updates at UBS and Jefferies healthcare investment conferences in Nov 2025. |
| Nov 03 | Quarterly earnings | Positive | +3.5% | Q3 2025 results showing YUTREPIA launch momentum and improved profitability metrics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company updates, including earnings and commercial metrics, have generally seen modest to strong positive price reactions, suggesting news flow has been received constructively.
Over the last several months, Liquidia has highlighted growing YUTREPIA momentum and expanding clinical activity. On Nov 3, 2025, Q3 2025 results showed strong product sales and improving profitability, with shares up 3.53%. Preliminary full-year 2025 YUTREPIA net sales on Jan 9, 2026 drove a 12.91% move. Multiple conference and clinical data presentations in late 2025 and early 2026 also produced smaller positive reactions, indicating investors have typically responded favorably to operational updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that it will report its full year 2025 financial results on Thursday, March 5, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
media@liquidia.com
